These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37630545)

  • 41. A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study.
    Serra N; Andriolo M; Butera I; Mazzola G; Sergi CM; Fasciana TMA; Giammanco A; Gagliano MC; Cascio A; Di Carlo P
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longitudinal Comparison of Automated SARS-CoV-2 Serology Assays in Assessing Virus Neutralization Capacity in COVID-19 Convalescent Sera.
    Niedrist T; Drexler C; Torreiter PP; Matejka J; Strahlhofer-Augsten M; Kral S; Riegler S; Gülly C; Zurl C; Kriegl L; Krause R; Berghold A; Steinmetz I; Schlenke P; Herrmann M
    Arch Pathol Lab Med; 2022 May; 146(5):538-546. PubMed ID: 35085385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.
    Resman Rus K; Korva M; Knap N; Avšič Županc T; Poljak M
    J Clin Virol; 2021 Jun; 139():104820. PubMed ID: 33865031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants.
    Chen CP; Huang KA; Shih SR; Lin YC; Cheng CY; Huang YC; Lin TY; Cheng SH
    Microbiol Spectr; 2022 Aug; 10(4):e0074322. PubMed ID: 35703556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients.
    Fujigaki H; Inaba M; Osawa M; Moriyama S; Takahashi Y; Suzuki T; Yamase K; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Doi Y; Saito K
    J Immunol; 2021 May; 206(10):2393-2401. PubMed ID: 33941657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
    Ismail A; Shurrab FM; Al-Jighefee HT; Al-Sadeq DW; Qotba H; Al-Shaar IA; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Front Biosci (Landmark Ed); 2021 Jul; 26(7):198-206. PubMed ID: 34340267
    [No Abstract]   [Full Text] [Related]  

  • 47. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
    Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
    Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
    Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
    Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
    Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
    To KK; Tsang OT; Leung WS; Tam AR; Wu TC; Lung DC; Yip CC; Cai JP; Chan JM; Chik TS; Lau DP; Choi CY; Chen LL; Chan WM; Chan KH; Ip JD; Ng AC; Poon RW; Luo CT; Cheng VC; Chan JF; Hung IF; Chen Z; Chen H; Yuen KY
    Lancet Infect Dis; 2020 May; 20(5):565-574. PubMed ID: 32213337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
    Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
    Front Immunol; 2021; 12():724763. PubMed ID: 34489978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure.
    Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; Aini TE; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D
    medRxiv; 2020 Aug; ():. PubMed ID: 32817969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals.
    Younes S; Al-Jighefee H; Shurrab F; Al-Sadeq DW; Younes N; Dargham SR; Al-Dewik N; Qotba H; Syed M; Alnuaimi A; Yassine HM; Tang P; Abu-Raddad LJ; Nasrallah GK
    Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33504067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiplexed, quantitative serological profiling of COVID-19 from a drop of blood by a point-of-care test.
    Heggestad JT; Kinnamon DS; Olson LB; Liu J; Kelly G; Wall SA; Fontes CM; Joh DY; Hucknall AM; Pieper C; Naqvi IA; Chen L; Que LG; Oguin T; Nair SK; Sullenger BA; Woods CW; Sempowski GD; Kraft BD; Chilkoti A
    medRxiv; 2020 Nov; ():. PubMed ID: 33173900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children.
    Hachim A; Gu H; Kavian O; Kwan MY; Chan WH; Yau YS; Chiu SS; Tsang OT; Hui DS; Ma F; Lau EH; Cheng SM; Poon LL; Peiris JM; Valkenburg SA; Kavian N
    medRxiv; 2021 Jan; ():. PubMed ID: 33655259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
    Peluso MJ; Takahashi S; Hakim J; Kelly JD; Torres L; Iyer NS; Turcios K; Janson O; Munter SE; Thanh C; Nixon CC; Hoh R; Tai V; Fehrman EA; Hernandez Y; Spinelli MA; Gandhi M; Palafox MA; Vallari A; Rodgers MA; Prostko J; Hackett J; Trinh L; Wrin T; Petroplolous CJ; Chiu CY; Norris PJ; DiGermanio C; Stone M; Busch MP; Elledge SK; Zhou XX; Wells JA; Shu A; Kurtz TW; Pak JE; Wu W; Burbelo PD; Cohen JI; Rutishauser RL; Martin JN; Deeks SG; Henrich TJ; Rodriguez-Barraquer I; Greenhouse B
    medRxiv; 2021 Mar; ():. PubMed ID: 33688675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.
    Kim D; Biancon G; Bai Z; VanOudenhove J; Liu Y; Kothari S; Gowda L; Kwan JM; Buitrago-Pocasangre NC; Lele N; Asashima H; Racke MK; Wilson JE; Givens TS; Tomayko MM; Schulz WL; Longbrake EE; Hafler DA; Halene S; Fan R
    bioRxiv; 2022 Sep; ():. PubMed ID: 36093346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.